Urinary Incontinence Therapeutics Market Urinary Incontinence Therapeutics Market Research

Urinary Incontinence Therapeutics Market Research Report : Forecast 2025
Urinary incontinence, an involuntary leakage of urine, is a very common problem especially among
people over 50 years of age. As per the American Academy of Family Physicians (AAFP), over 26
million Americans experience urinary incontinence at some point in their lives. This condition
depends on the incontinence type and severity, along with its causative reason. Weakened bladder,
damaged pelvic muscles, and cancer are some of the causes of urinary incontinence. This problem if
not treated, affects the social, economic, and emotional life of persons affected by it, as chronic
urinary incontinence can have a serious impact on overall health. The urinary incontinence condition
is diagnosed using urodynamic testing or pelvic ultrasound. If diagnosed, the treatment for urinary
incontinence involves a combination of various exercises along with medications.
The global urinary incontinence therapeutics market is expected to be driven by rising demand for
treatment of urinary disorders, along with combinational therapies with improved pharmacokinetic
and pharmacodynamic properties. Furthermore, rise in geriatric population, awareness initiatives
along with invention of effective therapeutics from years of research and development by
manufacturers, is expected to steer the growth of the global urinary incontinence therapeutics market.
However, difficulty in disease diagnosis, along with negligence about urinary incontinence disorders
is anticipated to restrain the market.
The global urinary incontinence therapeutics market has been classified on the basis of urinary
incontinence type, therapeutic class, and distribution channels. Based on the type of urinary
incontinence, the market has been categorized into stress urinary incontinence, urge urinary
incontinence, functional urinary incontinence, overflow urinary incontinence, and mixed urinary
incontinence. Among these segments, stress urinary incontinence affects more than 30 million
Americans, and its prevalence is higher in women. Based on therapeutic class, the market has been
divided into anticholinergic/antispasmodic agents, skeletal muscle relaxants, antidepressants, alpha
blockers, and others. The others segment includes, but is not limited to beta-3 adrenergic agonists,
topical estrogens, and serotonin – nor-epinephrine reuptake inhibitors. Recent advances in these
therapeutic classes include the marketing of M3 specific anticholinergic drugs, which have low side
effects due to increased bladder receptor sensitivity. Based on distribution channels, the global urinary
incontinence therapeutics market has been segmented into hospital pharmacy stores, retail pharmacy
stores, and online pharmacies.
Browse full report on Urinary Incontinence Therapeutics Market -
http://www.transparencymarketresearch.com/urinary-incontinence-therapeutics-market.html
The major challenge in the global urinary incontinence therapeutics market is the efficacy of these
medications along with reducing their adverse effects. Recent new pharmacogenic advances in
introduction of transdermal medications with better efficacy and tolerability than the conventional
oral therapeutics serves as a major opportunity to the market. Counseling efforts from manufacturers
with the help of various social organizations or NGOs is seen as a rising trend in the global urinary
incontinence therapeutics market, which in turn is expected to increase therapeutic treatment